Success Metrics

Clinical Success Rate
95.7%

Based on 22 completed trials

Completion Rate
96%(22/23)
Active Trials
3(11%)
Results Posted
59%(13 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_1
7
26%
Ph phase_3
1
4%
Ph phase_2
13
48%
Ph phase_4
6
22%

Phase Distribution

7

Early Stage

13

Mid Stage

7

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
7(25.9%)
Phase 2Efficacy & side effects
13(48.1%)
Phase 3Large-scale testing
1(3.7%)
Phase 4Post-market surveillance
6(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.7%

22 of 23 finished

Non-Completion Rate

4.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

27

all time

Status Distribution
Active(3)
Completed(22)
Terminated(1)
Other(1)

Detailed Status

Completed22
Recruiting3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
3
Success Rate
95.7%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (25.9%)
Phase 213 (48.1%)
Phase 31 (3.7%)
Phase 46 (22.2%)

Trials by Status

completed2281%
terminated14%
recruiting311%
unknown14%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT05781711Phase 2

Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

Completed
NCT06113640Phase 2

Montelukast in Parkinson Disease

Recruiting
NCT06785298Phase 2

Fexofenadine as Adjuvant Therapy in Parkinson Disease

Recruiting
NCT07001150Phase 2

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Recruiting
NCT04052776Phase 1

Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Completed
NCT02513485Phase 4

Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa

Completed
NCT01663935Phase 2

Vision Response to Dopamine Replacement

Terminated
NCT01393457Phase 2

Cognitive Remediation for Cocaine Dependence

Completed
NCT01484990Phase 1

A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Completed
NCT00218023Phase 2

Medications for Stopping Cocaine Dependence and Preventing Relapse

Completed
NCT02170376Phase 1

The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics

Completed
NCT02837640Phase 2

Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa

Unknown
NCT00789672Phase 2

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

Completed
NCT01190813Phase 3

Levodopa for the Treatment of Residual Amblyopia

Completed
NCT01568047Phase 2

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

Completed
NCT01533116Phase 1

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Completed
NCT01519284Phase 1

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Completed
NCT01840423Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers

Completed
NCT01568034Phase 2

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Completed
NCT01688089Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
27